Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.

Abstract

BACKGROUND:

GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have shown to reduce the risk of major adverse cardiovascular events (MACE), death and worsening nephropathy when added to standard of care. However, these two dug classes differ in efficacy and safety. We compared the effectiveness and safety profile of GLP-1 RA and SGLT-2i in a large and unselected cohort of patients with type 2 diabetes resident in Lombardy from 2015 to 2020.

METHODS:

Using linkable administrative health databases, we included patients aged 50 years and older initiating GLP-1 RA or SGLT-2i. Clinical events were: death, hospital admission for myocardial infarction (MI), stroke, heart failure (HF), and renal disease as individual and composite outcomes (MACE-3: all cause-death, non-fatal MI, non-fatal stroke; MACE-4: MACE-3 plus unstable angina). Outcomes were evaluated separately in subjects with and without previous cardiovascular (CV) diseases. Treatments were compared using Cox proportional hazards regression model after Propensity Score Matching (PSM) in both intention-to-treat (ITT) and per protocol (PP) analyses. Serious adverse events were also evaluated.

RESULTS:

The analysis comprised 20,762 patients per cohort. The ITT analysis showed a significant risk reduction for non-fatal MI (HR 0.77; CI 95% 0.66-0.90), MACE-3 (HR 0.91; CI 95% 0.84-0.98), and MACE-4 (HR 0.92; CI 95% 0.86-0.99) in GLP-1RA compared with SGLT-2i users, while no difference was reported in the incidence of HF hospitalization and stroke between the two cohorts. Similar benefits were found in the subgroup of patients without previous CV diseases only. PP analysis largely confirmed the main results. The incidence of serious adverse events was low in both cohorts (< 1%).

CONCLUSIONS:

GLP-1RA showed to be equally safe and more effective than SGLT-2i in reducing the risk of MACE-3, MACE-4 and MI. This study adds to the growing body of real-world evidence addressing the specific clinical properties of GLP-1RA and SGLT-2i in everyday practice to tailor treatment to the individual patient.

• Authors: Marta Baviera, Andreana Foresta, Pierluca Colacioppo, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Stefano Genovese, Irene Caruso, Francesco Giorgino
• Journal: Cardiovascular diabetology (Cardiovasc Diabetol) Vol. 21 Issue 1 Pg. 162 (08 24 2022) ISSN: 1475-2840 [Electronic] England
• PMID: 35999556 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Hypoglycemic Agents
• Sodium-Glucose Transporter 2 Inhibitors
• Glucagon-Like Peptide 1

Topics

• Aged
• Cardiovascular Diseases (diagnosis, epidemiology, prevention & control)
• Cohort Studies
• Diabetes Mellitus, Type 2 (diagnosis, drug therapy, epidemiology)
• Glucagon-Like Peptide 1 (therapeutic use)
• Glucagon-Like Peptide-1 Receptor (agonists)
• Humans
• Hypoglycemic Agents (adverse effects)
• Middle Aged
• Sodium-Glucose Transporter 2 Inhibitors (adverse effects)
• Stroke (diagnosis, epidemiology, prevention & control)